In conclusion, we can say that our results suggest that TLR5 could be potentially considered as a biomarker for COPD and LC development with functional relevance, which is reflected in increased sensitivity to chemotherapeutic drugs frequently applied in lung cancer treatment. This evidence concerns the gene TLR5 and lung carcinoma.